Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fenofibrate: metabolic and pleiotropic effects.

Vasilis Tsimihodimos1, George Miltiadous, Stella S Daskalopoulou

  • 1Department of Internal Medicine, Medical School, University of Ioannina, 451 10 Ioannina, Greece.

Current Vascular Pharmacology
|January 11, 2005
PubMed
Summary

Fenofibrate, a fibric acid derivative, effectively manages dyslipidaemia and improves associated vascular risk factors. It offers antiatherogenic benefits beyond lipid modification, proving useful in various patient groups and combinable with statins.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The role of fibrate treatment in dyslipidemia: an overview.

Current pharmaceutical design·2013
Same author

Ezetimibe therapy for dyslipidemia: an update.

Current pharmaceutical design·2013
Same author

Colesevelam: a new and improved bile acid sequestrant?

Current pharmaceutical design·2013
Same author

Hydrochlorothiazide vs. chlorthalidone as the optimal diuretic for the management of hypertension.

Current pharmaceutical design·2013
Same author

PCSK9 inhibition - a novel mechanism to treat lipid disorders?

Current pharmaceutical design·2013
Same author

Combined dyslipidemia: should the focus be LDL cholesterol or atherogenic dyslipidemia?

Current pharmaceutical design·2013

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Metabolic Disorders

Background:

  • Disturbances in lipoprotein metabolism are key risk factors for vascular events.
  • Dyslipidaemia often coexists with endothelial dysfunction, hypertension, inflammation, and hyperuricaemia, accelerating atherosclerosis.
  • Ideal lipid-modifying drugs should address both lipoprotein metabolism and these coexisting abnormalities.

Purpose of the Study:

  • To review the evidence for fenofibrate's lipid-modifying and other antiatherogenic actions.
  • To assess fenofibrate's utility in primary and secondary dyslipidaemias.
  • To evaluate fenofibrate's role in combination therapy for refractory dyslipidaemia.

Main Methods:

  • Review of current scientific literature on fenofibrate.

Related Experiment Videos

  • Analysis of studies on fenofibrate's effects on lipoprotein metabolism.
  • Examination of evidence regarding fenofibrate's impact on non-lipid cardiovascular risk factors.

    • Main Results:

    • Fenofibrate, a peroxisome proliferator-activated receptor alpha (PPARα) activator, effectively modifies lipids.
    • Fenofibrate demonstrates additional antiatherogenic effects beyond lipid management.
    • Studies support fenofibrate's use in primary and secondary dyslipidaemias, including those linked to diabetes, metabolic syndrome, and HIV.

    Conclusions:

    • Fenofibrate is a valuable therapeutic option for patients with primary and secondary dyslipidaemias.
    • Fenofibrate's pleiotropic effects contribute to its antiatherogenic profile.
    • Combination therapy with statins is a viable strategy for refractory dyslipidaemia.